The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Updated survival results of the randomized phase II study comparing cisplatin/capecitabine (CX) with epirubicin plus CX (ECX) in advanced gastric cancer (AGC).
Taekyu Lim
Disclosure not yet available
Jina Yun
Disclosure not yet available
Jeeyun Lee
Disclosure not yet available
Se Hoon Park
Disclosure not yet available
Joon Oh Park
Disclosure not yet available
Young Suk Park
Disclosure not yet available
Ho Yeong Lim
Disclosure not yet available
Won Ki Kang
Disclosure not yet available